-
Uncategorized2 weeks agoFour scientists awarded $3m for tau-driven disease research
A group of charities have announced $3 million in grants to fund four innovative research projects over two years, stemming from the 2026 Tauopathy Challenge Workshop. ...
-
Uncategorized2 weeks ago
BMS’ neuro renaissance was built on back of Celgene mega-merger
Well-known for its oncology efforts and making recent headlines for a rumored mega merger with AstraZeneca, Bristol Myers Squibb is also dedicating considerable resources to neurological...
-
Uncategorized2 weeks ago
China poses increasing security risk as US biotech innovation edge erodes
The U.S. is scrambling to compete with a strategically positioned China on the biotech stage as the Asian country surpasses America in biomedical research and clinical...
-
Uncategorized2 weeks agoStockWatch: Revolution Shares Stay Flat Despite Historic FDA Approval of Oral Pancreatic Cancer Therapy
Revolution Medicines (Nasdaq: RVMD) appeared to have the makings of another strong stock surge this past week when the FDA approved the company’s historic oral therapy...
-
Uncategorized3 weeks ago
Navigating regulatory fragmentation in the convergence of synthetic biology, artificial intelligence, and automation
Post Content
-
Uncategorized3 weeks ago
Molecular Pathways Driving Autoantibody Production Following SARS-CoV-2 Infection Identified
When the immune system encounters a virus, it produces antibodies designed to recognize and eliminate the invader. But in some people infected with SARS-CoV-2 the immune...
-
Uncategorized3 weeks agoModerna raises $2.6B to support cancer work; FDA clears updated COVID vaccines
Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study data were “inadvertently” published ahead of...
-
Uncategorized3 weeks ago
‘Worse than expected’ Wainua data muddies water for TTR silencers
AstraZeneca and Ionis Pharmaceuticals’ data drop divulging more details from its highly watched Phase 3 transthyretin silencer trial “further confuses the picture” for Wainua when combined...
-
Uncategorized3 weeks ago
BioXcel files for bankruptcy, will sell assets to Teva for up to $125M
Teva Pharmaceuticals is the ‘stalking horse bidder’ to kick off the auction process for BioXcel Therapeutics’ AI-derived assets as the biotech files for Chapter 11 bankruptcy.
-
Uncategorized3 weeks ago
BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test
Following Merck and Moderna’s phase 3 triumph with a Keytruda-paired personalized mRNA cancer vaccine, a similar shot from BioNTech and Genentech has faltered in a reminder...
Ensuring safety and accountability in China’s biomedical translation system
Blood centers can help biopharma scale cell and gene therapies
Psychedelics at FDA, Mike Davis’ CDER and translating tRNAs — a BioCentury podcast
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
